Clinical Research Directory
Browse clinical research sites, groups, and studies.
EC-104 Intravitreal Implant for the Treatment of Diabetic Macular Edema
Sponsor: Eclipse Life Sciences, Inc.
Summary
This is a prospective, randomized, subject- and evaluator-masked, Phase 2, multicenter study comparing the safety and efficacy of EC-104-6M high-dose (fluocinolone acetonide \[FA\] 0.14 mg) implant and EC-104-4M low-dose (FA 0.092 mg) implant to Ozurdex® (dexamethasone intravitreal (IVT) implant, 0.7 mg) in subjects with diabetic retinopathy (DR) and center-involving diabetic macular edema (DME), with prior suboptimal clinical response to IVT anti-VEGF therapy who have been previously treated with locally administered corticosteroids without a clinically significant rise in intraocular pressure (IOP).
Official title: A Randomized, Controlled, Subject- and Evaluator-Masked, Phase 2 Clinical Trial Comparing EC-104 Intravitreal Implant to Ozurdex® for the Treatment of Diabetic Macular Edema (BETTIS-1)
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
75
Start Date
2024-08-19
Completion Date
2025-12-31
Last Updated
2025-01-22
Healthy Volunteers
No
Conditions
Interventions
EC-104 high dose
Intravitreal injection
EC-104 low dose
Intravitreal injection
Dexamethasone intravitreal implant
Marketed product intravitreal injection
Locations (1)
Retina Associates of Florida, LLC
Tampa, Florida, United States